Imaging-guided immunotherapy for esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether special PET/CT scans can help predict how well immunotherapy works before surgery for esophageal cancer. It aims to improve treatment planning by identifying patients who may need additional therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have esophageal squamous cell carcinoma, confirmed by biopsy.
- Your cancer must be stage II to IVA and considered removable by surgery.
- You need to have two types of PET/CT scans before starting treatment.
- You must be between 18 and 75 years old.
- You must be generally healthy enough for surgery and have adequate organ function.
- You must not have received any prior cancer treatment.
- You must have a body mass index (BMI) of at least 18.5 (unless corrected with nutritional support).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug called adebrelimab (with other drugs) before surgery can help shrink the tumor and improve outcomes for people with a certain type of esophageal cancer. The goal is to make surgery more effective and potentially reduce the chance of cancer coming back.
This trial tests adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination shrinks tumors more and improves outcomes.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.